Osimertinib Mesylate

Type: API

Usage: Lung cancer

Technical description
Osimertinib mesylate is a methanesulfonate (mesylate) salt prepared from equimolar amounts of osimertinib and methanesulfonic acid. It is used for treatment of EGFR T790M mutation positive non-small cell lung cancer. It has a role as an antineoplastic agent and an epidermal growth factor receptor antagonist. It contains an osimertinib(1+).

IUPAC name: N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic acid.

.

Molecular formula: C₂₉H₃₇N₇O₅S

Molecular Weight: 595.7 g/mol

Class: It is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

Synonyms: AZD-9291 mesylate, Mereletinib mesylate.